| 0.2313 -0.023 (-8.97%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.34 | 1-year : | 0.44 |
| Resists | First : | 0.29 | Second : | 0.37 |
| Pivot price | 0.22  |
|||
| Supports | First : | 0.15 | Second : | 0.12 |
| MAs | MA(5) : | 0.24 |
MA(20) : | 0.23 |
| MA(100) : | 0.5 |
MA(250) : | 5.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49 |
D(3) : | 46 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 13 | Low : | 0.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABP ] has closed below upper band by 47.0%. Bollinger Bands are 75.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 98 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.25 - 0.25 | 0.25 - 0.25 |
| Low: | 0.23 - 0.23 | 0.23 - 0.23 |
| Close: | 0.23 - 0.23 | 0.23 - 0.23 |
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Fri, 16 May 2025
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Thu, 15 May 2025
Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Wed, 30 Apr 2025
ABP stock plunges to 52-week low, touches $0.23 - Investing.com
Sun, 27 Apr 2025
Abpro and Celltrion Reveal Promising Preclinical Data for Bispecific T-Cell Engager ABP-102/CT-P72 Targeting HER2-Positive Cancers - Nasdaq
Sun, 27 Apr 2025
Cancer Drug Shows 2X Better Tumor Suppression in Breakthrough Study | ABP Stock News - Stock Titan
Tue, 08 Apr 2025
Abpro Holdings faces Nasdaq delisting over share price - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 3.019e+007 (%) |
| Held by Institutions | 48.3 (%) |
| Shares Short | 55 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.97e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 464.4 % |
| Return on Equity (ttm) | -213 % |
| Qtrly Rev. Growth | 183000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.02 |
| Dividend | 0 |
| Forward Dividend | 157880 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|